- Phase III study showed sustained proteinuria reduction at one year with favorable safety1
- Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3
- C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4
- Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
Reported Earlier, Novartis Secures Third FDA Approval For Oral Fabhalta In Rare Kidney Disease C3G
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 319
Write a comment
Comment(0)
Reason For Report